The FDA has approved Vraylar (cariprazine) capsules, from Allergan, to treat schizophrenia and bipolar disorder in adults. The efficacy of...
The FDA has approved the supplemental New Drug Application (sNDA) for Vraylar (cariprazine), as reported byAllergan plc.
Allergan plc announced that the FDA has accepted for review the company's supplemental New Drug Application (sNDA) for Vraylar (cariprazine),...
AbbVie announced top-line results from two Phase III clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of Vraylar (cariprazine) as an adjunctive treatment for patients with major depressive disorder (MDD).
AbbVie announced that the FDA has approved Vraylar (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.
Allergan plc and Gedeon Richter Plc. have announced that the FDA has approved a supplemental New Drug Application (sNDA) for...
AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy.
Allergan plc announced that the FDA has accepted for filing the company's supplemental New Drug Application (sNDA) for Vraylar (cariprazine),...
AbbVie announced it will present positive data from a Phase III trial of cariprazine (Vraylar; 1.5 mg/day), Study 3111-301-001, for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant therapy.